Literature DB >> 12214081

Recent advances in the understanding of the role of synaptic proteins in Alzheimer's Disease and other neurodegenerative disorders.

Eliezer Masliah1.   

Abstract

Synaptic damage is an early pathological event common to many neurodegenerative disorders such as Alzheimer's disease (AD) and is the best correlate to the cognitive impairment. Several molecules involved in AD and in other neurodegenerative disorders play an important role in synaptic function and when misfolded aggregate and form amyloid fibrils. Synaptic proteins with an amyloid domain include amyloid beta-protein precursor, prion protein, huntingtin, ataxin-1 and alpha-synuclein. Two of the possible mechanisms by which alterations in synaptic proteins lead to synapse damage are: 1) misfolded or aggregated synaptic molecules have lost their normal function and/or 2) they have gained a toxic capacity. Recent studies support the possibility that while oligomers are toxic, polymers might be inactive. The mechanisms by which oligomers trigger synapse loss could be related to their ability to triggers stress signals once they enter the nucleus and/or accumulate at the endoplasmic reticulum.

Entities:  

Year:  2001        PMID: 12214081     DOI: 10.3233/jad-2001-3117

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  18 in total

Review 1.  Molecular pathogenesis of spinocerebellar ataxia type 6.

Authors:  Holly B Kordasiewicz; Christopher M Gomez
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 2.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 3.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

4.  AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy.

Authors:  A Borreca; V Latina; V Corsetti; S Middei; S Piccinin; F Della Valle; R Bussani; M Ammassari-Teule; R Nisticò; P Calissano; G Amadoro
Journal:  Mol Neurobiol       Date:  2018-03-05       Impact factor: 5.590

5.  Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease.

Authors:  Andrew O Koob; Gideon M Shaked; Andreas Bender; Alejandro Bisquertt; Edward Rockenstein; Eliezer Masliah
Journal:  Brain Res       Date:  2014-10-19       Impact factor: 3.252

6.  Amyloid-β protein modulates insulin signaling in presynaptic terminals.

Authors:  David Heras-Sandoval; Patricia Ferrera; Clorinda Arias
Journal:  Neurochem Res       Date:  2012-05-26       Impact factor: 3.996

Review 7.  The shifting patterns of HIV encephalitis neuropathology.

Authors:  I P Everall; L A Hansen; E Masliah
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

Review 8.  Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy.

Authors:  Janelle L Cooper
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Molecular mechanisms of neurodegeneration in Alzheimer's disease.

Authors:  Leslie Crews; Eliezer Masliah
Journal:  Hum Mol Genet       Date:  2010-04-22       Impact factor: 6.150

Review 10.  APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Authors:  Leslie Crews; Edward Rockenstein; Eliezer Masliah
Journal:  Brain Struct Funct       Date:  2009-11-29       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.